BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment

Group 1 - BioNTech SE is a significant player in mRNA-based cancer therapies and vaccines for virus immunization [1] - The company plans to expand its oncology pipeline by adding candidates such as FixVac, iNeST, and BNT327 by 2025 [1]